submit to the journals

Haematological Malignancies Journal Articles, Videos And Insights

Haematological Malignancies: FEATURED Articles

flipper_slider

Haematological Malignancies: Latest Articles

Haematological Malignancies: INSIGHTS

The touchONCOLOGY website provides a selection of resources to inform clinicians and patients about the latest developments in the field. The following are quick, non peer-reviewed, opinion-based updates addressing current trends and opinion on the most recent advances in the area of oncology:

Meeting Proceedings
Efficacy and Safety of CD22-directed CAR-T cell Therapy in Children with Refractory or Relapsed B Acute Lymphoblastic Leukaemia Katrina Mountfort
Senior Medical Writer, Touch Medical Media, UK
Meeting Proceedings
The Prognostic Significance of TP-53 Clone Size in Relapsed/Refractory CLL Patients in the MURANO Study Katrina Mountfort
Senior Medical Writer, Touch Medical Media, UK
Meeting Proceedings
New Combined Treatment Options for Relapsed/Refractory Multiple Myeloma – The OPTIMISMM Study Katrina Mountfort, Senior Medical Writer, Touch Medical Media, UK
Tim Sheldrick, Account Director and Advisory Editor, Touch Medical Media, UK
Insight
2017 – a Landmark Year for Food and Drug Administration Approvals for Haematological Malignancies Katrina Mountfort, Senior Medical Writer, Touch Medical Media, Reading, UK
Tim Sheldrick, Group Director and Advisory Editor, Touch Medical Media, Reading, UK

Haematological Malignancies: FEATURED VIDEOS

Editor's choice

touchONCOLOGY talks to Arnon P Kater from the Academisch Medisch Centrum Universiteit van Amsterdam about the MURANO study and the impact of TP53-mutated clone size on outcome of relapsed/refractory (R/R) CLL patients treated with venetoclax plus rituximab. 1. Why do chronic lymphocytic leukaemia (CLL) patients with alterations in the TP53 pathway represent an unmet clinical need? (0:10) 2. Could you tell us a little about venetoclax and its efficacy in CLL? (1:11) 3. What is the safety profile of venetoclax? (2:05) 4. What was the rationale for the investigation of the impact of clone size on outcomes in patients in the MURANO study? (2:56) 5. What were the findings of this investigation and what are the implications of these findings? (4:29) Speaker disclosures: Arnon P Kater has nothing to disclose in relation to this video interview. Filmed at the 23rd Annual Congress of the European Association of Hematology (EHA), Stockholm, Sweden, June 14–17 2018
Paul Richardson from the Dana-Farber Cancer Institute and Harvard Medical School provides an overview of the key findings of the OPTIMISMM trial and discusses the need for new treatment strategies in multiple myeloma. 1. Why is there a need for new combinations of therapies in relapsed/refractory multiple myeloma? (0:09) 2. Could you tell us a little about the study design and what doses were used? (2:51) 3. What were the efficacy and safety findings of the combination? (4:22) 4. What other combined therapies are being considered for future studies? (5:10) Speaker disclosures: Paul Richardson has nothing to disclose in relation to this video interview. Filmed at the 23rd Annual Congress of the European Association of Hematology (EHA), Stockholm, Sweden, June 14–17 2018

Haematological Malignancies: Latest Videos

Video List based on Category on Node Page

Latest Videos

touchONCOLOGY talks to Arnon P Kater from the Academisch Medisch Centrum Universiteit van Amsterdam about the MURANO study and the impact of TP53-mutated clone size on outcome of relapsed/refractory (R/R) CLL patients treated with venetoclax plus rituximab. 1. Why do chronic lymphocytic...
Annalisa Chiapella from Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino in Italy talks to touchONCOLOGY about patients with diffuse large B-cell lymphoma (DLBCL) with a TP53 mutation, and the aims and findings of the FIL-DLCL04 study to help tackle...
Paul Richardson from the Dana-Farber Cancer Institute and Harvard Medical School provides an overview of the key findings of the OPTIMISMM trial and discusses the need for new treatment strategies in multiple myeloma. 1. Why is there a need for new combinations of therapies in...
We catch up with editorial board member Willem Fibbe from Leiden University Medical Centre to discuss mesenchymal stromal cells and their therapeutic potential in the clinic. 1. What properties of mesenchymal stromal cells (MSCs) have led to the investigation of their therapeutic...
Editorial board member, Ian W Flinn from Sarah Cannon, Tennesse Oncology, in Nashville, TN, talks to us about risk of relapse and promising treatments for relapsed/refractory CLL and advances in the treatment of DLBCL and follicular lymphoma. 1. What are the most important unmet needs...
We catch up with our US Editor-in-Chief to discuss advances in molecular targets and treatment in multiple myeloma, as well as important updates in the latest NCCN guidelines. 1. What do you consider the most important unmet needs in the treatment of multiple myeloma? (0:11) 2. What...

LATEST TWEETS

Conference Highlights